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Abstract
Background: Malignant acrospiroma is a rare tumor of the eccrine sweat glands accounting for around 6% of all
malignant eccrine tumors. Typically, it presents as large ulcerated nodules, and diagnosis can be challenging as it
has great overlap with its benign counterpart.
Case presentation: We herein report a case of acral malignant acrospiroma, initially treated with surgical excision
and adjuvant radiotherapy. After metastatic disease was confirmed, subject received multiple lines of chemo- as
well as targeted therapy. Genomic testing was also done using next generation sequencing.
Conclusion: To the best of our knowledge, this is the first case of acral malignant acrospiroma with reported next
generation sequencing results.
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Background
Malignant acrospiromas arise from the intradermal duct
of eccrine sweat glands and account for approximately
6% of malignant eccrine tumors [1] compared to their
more prevalent benign counterparts [2]. They appear in
the literature under multiple nomenclatures, including
clear cell hidradenocarcinoma, malignant clear cell
hidradenoma, and malignant hidradenoma [3, 4]. Dis-
ease usually manifests in middle-age [5]. Some reports
show disease is more common in females [6], but there
does not seem to be an obvious gender predominance
[4, 7, 8]. Lesions typically present as slow growing nod-
ules that can ulcerate and drain [6, 9]. They range in size
from 0.5 to 10 cm [6, 9]. They usually involve the head,
neck, and extremities; less common sites include the
chest and breasts [1, 4, 5, 9, 10].
This tumor has an aggressive behavior with more than
50% local recurrence rates [11]. Wide surgical excision is
the treatment of choice [12–14]. The efficacy of adjuvant
chemotherapy is controversial. Adjuvant radiotherapy
has been shown successful in some cases [4, 12, 13].
With the advent of targeted therapy, genetic profiling is
becoming a more attractive tool. EGFR overexpression
was observed by Piris et al. in 3 out of 12 malignant
hidradenomas [15]. However, there has been no reports
of next generation sequencing. We herein report a case
of acral malignant acrospiroma initially treated with
surgical excision and adjuvant radiotherapy. After metas-
tases was discovered, subject received multiple lines of
chemotherapy. We also tested the tumor for genomic
alterations using next generation sequencing.
Case presentation
A 73-year-old White male was referred to our institution
for the treatment of metastatic malignant acrospiroma.
He initially presented in 2009 with a nodular lesion on
the dorsal aspect of the left great toe. An excisional bi-
opsy of the lesion showed subcutaneous tissue contain-
ing multilobular and ill-defined tumor. The pathologic
diagnosis was consistent with acrospiroma; margins were
involved (Fig. 1a and b). Wide surgical excision was sub-
sequently performed to clear the margins and the patient
was followed by clinical surveillance. Six months later,
the patient developed local recurrence and the patho-
logical findings were similar to the original biopsy. At
this time, he was treated with radiation therapy (received
40 Gray) followed by clinical surveillance again.
Three years later, he presented with left groin mass. A
positron emission tomography-computed tomography
(PET-CT) scan showed uptake in the left inguinal lymph
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nodes and multiple hepatic lesions. A biopsy from the
hepatic lesion was consistent with metastatic acrospir-
oma (Fig. 1c). His laboratory studies were within normal
limits, except for an elevated carcinoembryonic antigen
(CEA) of 206.1 ng/mL (normal is less than 5.1 ng/mL).
Patient was subsequently started on systemic chemo-
therapy. He was initially treated with capecitabine. After
2 months of therapy, however, disease progressed and
treatment was discontinued. The second line of chemo-
therapy utilized carboplatin. He completed a total of
6 cycles on this combination until disease progression.
On progression, he was referred to our institution for
consideration of experimental therapy. Tissue from hep-
atic metastasis was sent for genomic profiling using next
generation sequencing Knight diagnostic gene panel.
Unfortunately, no actionable genomic alterations were
identified. Genes tested included EGFR, ALK, BRAF,
JAK2, NOTCH1, NRAS, or PTEN (Table 1), and the
sequencing coverage ranged from 92.4 to 100%. Our
patient was then placed on a phase I trial utilizing a PI3
kinase AkT mTOR inhibitor and ultimately progressed
and succumbed to his disease.
Pathology
Sections from the initial diagnostic biopsy revealed
tumor that composed of epithelial cells with foci of clear
cell morphology and cystic changes, suggesting trichi-
lemmal differentiation (Fig. 1a and b). Some foci exhib-
ited a sclerotic stroma with cystic changes and others
showed mucinous stroma and mucinous changes within
the epithelial cells (mucinous metaplasia). There was no
ductal differentiation. The tumor showed pushing
boarders, focal infiltrative pattern and small areas of in-
creased pleomorphic features and atypia with mitotic ac-
tivity and focal necrosis. The surrounding connective
tissue margins were involved. No immunohistochemical
studies were performed and the pathological diagnosis
was that of acrospiroma with atypia suggesting foci of
malignant transformation. Apart from metastasis to liver,
all subsequent metastasis sites, focal and distant, showed
findings similar to those seen in the original biopsy. In a
specimen that showed liver metastasis (Fig. 1c), the
tumor exhibited more cells with clear cytoplasm and
hyperchromatic nuclei. Interspersed with the clear cells
is a small population of goblet cells which appear to
contain mucinous materials. Because of the clear cell
morphology in a small population, CD10 immunohisto-
chemical stain was also performed to exclude clear cell
type renal cell carcinoma, and it was negative.
Fig. 1 a Malignant cells are arranged in cords and sheets separated by a markedly desmoplastic stroma and extending deep into the dermis (H&E at
40X magnification). b Neoplastic cells showing squamous, sebaceous and mucinous differentiation. (H&E at 100X magnificent). c Liver tissue (upper)
with metastatic malignant acrospiroma (lower). The neoplastic cells have uniformly hyperchromatic nuclei (H&E at 400X magnification)
Table 1 Mutation screening by next generation sequencing on
tissue from hepatic metastasis∞
Gene Percentage of expected
sequencing coverage*
AKT1, BRAF, CDKN2A, DDR2, EGFR, ERBB2,
HRAS, JAK2, KDR, KRAS, MAP2K1, NRAS,







∞ No mutations were identified
*Percent of gene covered by a minimum of 100 sequence reads, as compared
with expected coverage based on data from 10 normal DNA samples
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Discussion and conclusion
Malignant acrospiroma is a rare tumor of the eccrine
sweat glands that usually displays an aggressive behavior.
Disease can arise de novo or transform from a previous
benign lesion. Our patient did not have a history of prior
malignancy. One of the challenges in establishing the
disease is that it is often mistaken for benign lesions,
and patients are monitored for some time before tumors
cause symptoms that prompt seeking medical attention.
Wenzel described a case of malignant acrospiroma that
was initially mistaken for osteomyelitis. The patient was
initially started on antibiotics before pathology on the
surgically excised digit confirmed malignancy [14]. In
other instances, disease masquerades as more common
malignant lesions, like malignant melanoma [16]. The
other challenge lies in complete sampling of the lesion.
Disease might be focal and/or may reside in the periph-
ery of the biopsied sample.
Wide surgical excision is the mainstay of treatment
[12]. Wildemore compared outcomes with Mohs micro-
graphic surgery to conventional surgery; all 19 patients
who underwent Mohs micrographic surgery had no local
recurrence at a 29-month follow up [16]. Our patient
was initially treated with surgical excision after the initial
biopsy showed positive margins. Even wide surgical exci-
sion, recurrence rates of as high as 50% have been docu-
mented [17]. Due to the aggressive nature and the
tendency for lymphatic invasion, some authors advocate
for prophylactic lymph node dissection [18]. Evidence is
lacking on the efficacy of adjuvant chemotherapy [19,
20]. Furthermore, whether the reported results are due
to a real response to chemotherapy or due to a slow
growth of the tumor is questionable. In a case of meta-
static disease, complete response was achieved after
3 months of capecitabine (1500 mg/m2 in a split daily
dose, on a 3-weeks-on/1-week-off schedule) [21]. Treat-
ment was complicated with grade 2 fatigue. At
24-month follow up, Lerner’s patient was disease free.
The use of second-line sunitinib was associated with an
8-month progression-free survival in one patient [22].
The role of radiotherapy appears to be more established
[4, 12, 13]. In one report of 3 patients who received ad-
juvant radiotherapy, 2 patients remained disease free at
27 and 35 months, respectively, after the completion of
treatment; the third died of rapidly progressive systemic
disease [23]. The dose of radiation was 70 Gray for the
surgical bed and 50 Gray for the regional lymphatic
chains.
With the advent of targeted therapy, the use of
genomics in the management of tumors has gained
popularity. Several mutations have been previously
identified in different cutaneous neoplasms, including
t(11;19) in clear cell hidradenomas, hidradenocarcino-
mas, and mucoepidermoid carcinomas [2, 24, 25],
resulting in a TORC1-MAML2 gene fusion; TP53 muta-
tions and amplification of the Her2/neu gene in hidrade-
nocarcinomas [25]; and BRAF-V600E in aggressive
digital papillary adenocarcinoma [26]. Despite reports of
using next generation sequencing in other cutaneous
neoplasms, there have been no reports on its application
in malignant acrospiroma. Unfortunately, although next
generation sequencing was conducted in our case, it
failed to show mutations that would mandate targeted
therapy. Furthermore, none of the aberrations described
in other cutaneous tumors were identified.
Our patient was treated with chemotherapy when his
disease metastasized. He then entered a phase I trial util-
izing a PI3 kinase AkT mTOR inhibitor. The patient was
treated on a phase I PI3K/AKt clinical trial that didn’t
require PI3K/AKt dysregulation. This was a dose finding
study and allowed patients with any tumor type regard-
less of their PI3K/AKt mutation status to be included.
The choice of PI3K/Akt was arbitrary as this is a com-
monly dysregulated pathway in cancer, and at the
current time there is no single test available to predict
PI3K/AKt dysregulation or response to Pi3K/Akt inhbi-
tors. However, he ultimately progressed and succumbed
to his disease. The lack of identified mutations might
explain the aggressive nature of the disease.
Malignant acrospiroma is a rare tumor that originates
from the eccrine sweat glands. Aggressive in its nature,
its diagnosis is challenging, and specific tumor markers
and gene mutations are not defined. Wide surgical exci-
sion, with or without prophylactic lymph node dissec-
tion, is the treatment of choice. Evidence is lacking on
the efficacy and/or advised regimen of chemoradiother-
apy. Prognosis is poor with systemic disease. More
studies are needed for the management of this disease.
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